ERBB2 expression was linked to unfavorable survival in glioma, ovarian, and pancreatic cancers but favorable survival in renal cancer (https://www.proteinatlas.org/ENSG00000141736-ERBB2/cancer), whereas TP53 expression showed a favorable association in breast and colorectal cancers (https://www.proteinatlas.org/ENSG00000141510-TP53/cancer). This evidence concerns the gene ERBB2 and colorectal cancer.